LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer

Li, Jian; Shi, Shun‐Bing; Shi, Weilin; Wang, Yi; Yu, Long-Chuan; Zhu, Liangjun; Ge, Li‐Ping

doi:10.1016/j.trsl.2013.09.010

Cited by 19 publications

(15 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a reduction in the number of CTCs after chemotherapy was also significantly associated with better outcomes in SCLC (66,94). Regarding the role of CTCs as biomarkers for therapeutic monitoring in NSCLC, comparisons between studies performed on samples collected before and after chemotherapy have consistently found that survival rates were significantly worse for patients with CTC counts that remained positive during treatment (95,96). In a group of patients treated with erlotinib and pertuzumab, the authors found that the decrease in CTC count upon treatment were significantly associated with disease response (91).…”

Section: Ctcs: Clinical Applicationsmentioning

confidence: 98%

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Calabuig¹,

Jantus‐Lewintre²,

Herreros‐Pomares³

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Liquid biopsies appear to be a reliable alternative to conventional biopsies that can provide both precise molecular data useful for improving the clinical management of lung cancer patients as well as a less invasive way of monitoring tumor behavior. These advances are supported by important biotechnological developments in the fields of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA). Analysis of CTCs and ctDNA may be useful in treatment selection, for response monitoring, and in studying resistance mechanisms. This review focuses on the most recent technological achievements and the most relevant clinical applications for lung cancer patients in the CTC and ctDNA fields, highlighting those that are already (or are close to) being implemented in daily clinical practice.

show abstract

Section: Ctcs: Clinical Applicationsmentioning

confidence: 98%

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Calabuig¹,

Jantus‐Lewintre²,

Herreros‐Pomares³

et al. 2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…Assessment of CTC at multiple time points might increase the predictive value of the assay. Li and collaborators (26) assessed the CTC status in 68 stage I-III NSCLC patients before surgery, after surgery and after completion of adjuvant chemotherapy. The LUNX mRNA whose expression is strictly limited to normal lung tissue and NSCLC was used as marker.…”

Section: Detection and Prognostic Value Of Ctc In Early Nsclcmentioning

confidence: 99%

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Gallo

Luca

Maiello

et al. 2017

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Several different studies have addressed the role of the circulating tumor cells (CTC) in nonsmall-cell lung cancer (NSCLC). In particular, the potential of CTC analysis in the early diagnosis of NSCLC and in the prediction of the outcome of patients with early and advanced NSCLC have been explored. A major limit of these studies is that they used different techniques for CTC isolation and enumeration, they employed different thresholds to discriminate between high-and low-risk patients, and they enrolled heterogeneous and often small cohort of patients. Nevertheless, the results of many studies are concordant in indicating a correlation between high CTC count and poor prognosis in both early and advanced NSCLC. The reduction of CTC number following treatment might also represent an important indicator of sensitivity to therapy in patients with metastatic disease. Preliminary data also suggest the potential for CTC analysis in the early diagnosis of NSCLC in high-risk individuals. However, these findings need to be confirmed in large prospective trials in order to be transferred to the clinical practice.The molecular profiling of single CTC in NSCLC might provide important information on tumor biology and on the mechanisms involved in tumor dissemination and in acquired resistance to targeted therapies. In this respect, xenografts derived from CTC might represent a valuable tool to investigate these phenomena and to develop novel therapeutic strategies.

show abstract

“…In a global metaanalysis, the appearance of pretreatment CTCs in patients with different stages of lung cancer correlated with lymph node status, distant metastasis, and TNM staging [64]. Longitudinal CTC monitoring has also shown that patients with more than one time point positive for CTCs had worse survival than those with conversion from CTC positive to CTC negative or persistently negative [65].…”

Section: Prognosis and Predictive Response To Treatmentmentioning

confidence: 99%

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Levy

Cordova

et al. 2016

The Oncologist

View full text Add to dashboard Cite

A firmer understanding of the genomic landscape of lung cancer has recently led to targeted, therapeutic advances in non-small cell lung cancer. Historically, the reference standard for the diagnosis and genetic interrogation for advanced-stage patients has been tissue acquisition via computed tomography-guided core or fine needle aspiration biopsy. However, this process can frequently put the patient at risk and remains complicated by sample availability and tumor heterogeneity. In addition, the time required to complete the diagnostic assays can negatively affect clinical care. Technological advances in recent years have led to the development of blood-based diagnostics or “liquid biopsies” with great potential to quickly diagnose and genotype lung cancer using a minimally invasive technique. Recent studies have suggested that molecular alterations identified in cell-free DNA (cfDNA) or circulating tumor DNA can serve as an accurate molecular proxy of tumor biology and reliably predict the response to tyrosine kinase therapy. In addition, several trials have demonstrated the high accuracy of microRNA (miRNA) platforms in discerning cancerous versus benign nodules in high-risk, screened patients. Despite the promise of these platforms, issues remain, including varying sensitivities and specificities between competing platforms and a lack of standardization of techniques and downstream processing. In the present report, the clinical applications of liquid biopsy technologies, including circulating tumor cells, proteomics, miRNA, and cfDNA for NSCLC, are reviewed and insight is provided into the diagnostic and therapeutic implications and challenges of these platforms.

show abstract

LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer

Cited by 19 publications

References 24 publications

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About